India’s CDMO Sector Poised for Global Surge as Pharma Diversifies from China
The global pharmaceutical landscape is undergoing a massive structural realignment as multinational companies seek to de-risk their supply chains away from China. Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this shift, positioned as the most reliable alternatives for global drugmakers.
The Strategic Shift Away from China
The movement toward diversifying manufacturing footprints is no longer a theoretical possibility but an active industry trend. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, the genesis of this shift began nearly two years ago, well before recent regulatory scrutinies involving Chinese giants like WuXi AppTec.
The inclusion of certain entities on regulatory watchlists has provided much-needed clarity for global pharmaceutical firms to accelerate their diversification strategies. As these companies seek to mitigate geopolitical and regulatory risks, India has become their "best bet." This transition is evidenced by the growing engagement between Indian CDMOs and global innovators, with many firms already actively relocating conversations and potential contracts to Indian soil.
Sai Life Sciences: Scaling Up for Global Demand
To capitalize on this landmark opportunity, Sai Life Sciences has announced a significant capital expenditure plan. The company intends to invest between ₹1,100 crore and ₹1,300 crore in capacity expansion by FY27. This expansion will be funded through a combination of internal accruals and debt, keeping the balance sheet healthy.
A key indicator of this growing partnership with global giants is the company's revenue mix. Over the last four years, the contribution from large global pharmaceutical companies has nearly doubled, rising from 28% to 49% of total revenue. This shift underscores a deeper integration of Indian players into the high-value workflows of the world's largest drugmakers.
Transitioning from Clinical to Commercial Manufacturing
A critical evolution in the Indian CDMO story is the shift in the nature of the work being performed. Historically, many global pharma companies utilized India primarily for clinical trial supplies. However, there is a noticeable movement toward using India for large-scale commercial manufacturing.
Sai Life Sciences has reported a substantial increase in its late-stage development pipeline. The company’s portfolio of Phase III and pre-registration molecules has grown from six to eleven in the past year. While the regulatory nature of pharmaceutical manufacturing means that these shifts in contracts take time to materialize in financial statements, the long-term pipeline suggests a robust upward trajectory.
Growth Outlook and Regulatory Timelines
Despite the optimistic landscape, industry leaders maintain a realistic view of the timelines involved. Because manufacturing involves stringent regulatory approvals and complex product transfer processes, the full impact of the China-plus-one strategy may not reflect in quarterly results immediately.
Sai Life Sciences has maintained its revenue growth guidance of a 15-20% CAGR. The company expects its performance to be weighted toward the second half of the fiscal year as new production facilities come online and reach optimal capacity utilization.
Key Takeaways
- Diversification Trend: Global pharma companies are actively moving manufacturing footprints from China to India to mitigate regulatory and supply chain risks.
- Shift to Commercial Scale: Indian CDMOs are evolving from providing clinical trial supplies to handling high-value, commercial-scale manufacturing for global innovators.
- Aggressive Expansion: Leading players like Sai Life Sciences are investing up to ₹1,300 crore in capacity to meet the growing demand for long-term pharmaceutical partnerships.